(Q33386506)

26 July 2017

title

Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms (English)

1 reference

26 July 2017

13

Barbara Pro

1 reference

26 July 2017

16

Hagop Kantarjian

1 reference

26 July 2017

6

Alessandra Ferrajoli

1 reference

26 July 2017

4

Stefan Faderl

1 reference

26 July 2017

12

Srdan Verstovsek

1 reference

26 July 2017

10

William Wierda

1 reference

26 July 2017

3

Susan O'Brien

1 reference

26 July 2017

1

Farhad Ravandi

1 reference

26 July 2017

9

Sherry Pierce

1 reference

26 July 2017

15

Michael Keating

1 reference

26 July 2017

14

Luis Fayad

0 references

Dimitrios P Kontoyiannis

series ordinal

11

object named as

Dimitrios Kontoyiannis

1 reference

26 July 2017

7

Xuelin Huang

1 reference

26 July 2017

2

Ahmed Aribi

1 reference

26 July 2017

8

Sergernne York

1 reference

26 July 2017

Dan Jones

5

1 reference

26 July 2017

language of work or name

English

0 references

publication date

5 October 2009

1 reference

26 July 2017

number of pages

6

1 reference

Journal of Clinical Oncology

inferred from page(s)

published in

1 reference

26 July 2017

volume

27

1 reference

26 July 2017

issue

32

1 reference

26 July 2017

page(s)

5425-5430

1 reference

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881363

Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881363

21 June 2018

Mature T-cell leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881363

Peripheral T-cell lymphomas: diagnosis and management

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881363

Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881363

Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881363

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881363

Human T-cell lymphotropic-I-associated leukemia/lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881363

Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881363

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881363

Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881363

Prolymphocytic leukaemia of B and T cell type.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881363

Deoxycoformycin in the treatment of mature T-cell leukaemias

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881363

Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881363

Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881363

Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881363

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881363

A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881363

Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881363

Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109).

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881363

Adult T-cell leukemia/lymphoma in London: clinical experience of 21 cases.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881363

New statistical strategy for monitoring safety and efficacy in single-arm clinical trials.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881363

A novel four-color PCR assay to assess T-cell receptor gamma gene rearrangements in lymphoproliferative lesions

31 October 2018

1 reference

12 December 2020

Hepatosplenic gamma/delta T-cell lymphoma in bone marrow. A sinusoidal neoplasm with blastic cytologic features

1 reference

12 December 2020

An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support

1 reference

12 December 2020

Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2009.22.6688

1 reference

26 July 2017

1 reference

26 July 2017

1 reference